Exagen Inc. (XGN)

Market Cap	68.73M
Revenue (ttm)	55.64M
Net Income (ttm)	-15.12M
Shares Out	17.90M
EPS (ttm)	-0.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	107,931
Open	4.210
Previous Close	4.240
Day's Range	3.710 - 4.120
52-Week Range	1.300 - 6.220
Beta	1.40
Analysts	Strong Buy
Price Target	7.50 (+95.31%)
Earnings Date	Mar 11, 2025

About XGN

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlap...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Sep 19, 2019
• Employees: 215
• Stock Exchange: NASDAQ
• Ticker Symbol: XGN
• Website: https://www.exagen.com

Financial Performance

In 2024, Exagen's revenue was $55.64 million, an increase of 5.89% compared to the previous year's $52.55 million. Losses were -$15.12 million, -36.19% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for XGN stock is "Strong Buy." The 12-month stock price forecast is $7.5, which is an increase of 95.31% from the latest price.

Price Target

$7.5

(95.31% upside)

Analyst Consensus: Strong Buy